Effects of change in high-density lipoprotein cholesterol by statin switching on glucose metabolism and renal function in hypercholesterolemia

Journal of Clinical Lipidology
Hirokazu KakudaNoboru Takekoshi

Abstract

Recent reports have suggested that high-density lipoprotein (HDL) is metabolically related to glucose metabolism and renal function. Statin administration clinically increases HDL cholesterol (HDL-C). To confirm that change in HDL-C by statin switching is associated with glucose metabolism and renal function in hypercholesterolemic patients. In hypercholesterolemic outpatients (n = 129) who had taken either statin, as atorvastatin, pitavastatin, or rosuvastatin and switched to another statin, the relationship of change in HDL-C to glycated hemoglobin and estimated glomerular filtration rate (eGFR) was assessed. Change in HDL-C did not significantly correlate with change in HbA1c, eGFR calculated from creatinine (eGFRcre), and eGFR calculated from cystatin C (eGFRcys). The subjects were then divided into 2 groups by change in HDL-C: no change or decrease in HDL-C (HD group) and increase in HDL-C (HI group). In the HI group, apolipoprotein A-1 (Apo A-1) and eGFRs were significantly increased by statin switching. There were significant differences in changes in HDL-C, Apo A-1, lipoprotein lipase, glycated hemoglobin, and eGFR calculated from creatinine between the groups. In the patients with impaired glucose tolerance or diabetes...Continue Reading

References

May 21, 2003·Circulation·Bharti MacknessMichael Mackness
Jun 25, 2005·Circulation Research·Gary F Lewis, Daniel J Rader
Feb 5, 2008·The Journal of Clinical Investigation·Liam R BrunhamMichael R Hayden
Nov 12, 2009·JAMA : the Journal of the American Medical Association·UNKNOWN Emerging Risk Factors CollaborationJohn Danesh
Jun 2, 2010·Journal of Atherosclerosis and Thrombosis·Shizuya YamashitaMakoto Nishida
Nov 26, 2010·Current Opinion in Lipidology·Arnold von Eckardstein, Rahel A Sibler
Feb 22, 2012·Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine·Keijiro SakuKeita Noda
Feb 26, 2014·Scandinavian Journal of Clinical and Laboratory Investigation·Hirokazu KakudaNoboru Takekoshi
Jan 13, 2015·Atherosclerosis. Supplements·Lorenzo Arnaboldi, Alberto Corsini

❮ Previous
Next ❯

Citations

Oct 2, 2019·International Journal of Clinical Practice·Michael G KirbyDerek J Rosario
Mar 30, 2021·Cancer Management and Research·Su-Ping GuoHui Chang

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.